Cannara Biotech 배당금 및 환매

배당금 기준 확인 0/6

Cannara Biotech 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

0.8%

환매 수익률

총 주주 수익률	0.8%
미래 배당 수익률	n/a
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively

Oct 29

Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings

Aug 22

Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue

Aug 21

Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?

Jul 14

Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

May 09

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

Feb 28

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Apr 10

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

Jan 26

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

Jan 27

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Dec 10

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

Mar 16

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Jan 22

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Dec 18

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 LOVE 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: LOVE 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Cannara Biotech 시장 대비 배당 수익률

LOVE 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (LOVE)	n/a
시장 하위 25% (CA)	1.8%
시장 상위 25% (CA)	6.2%
업계 평균 (Personal Products)	2.8%
애널리스트 예측 (LOVE) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 LOVE 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 LOVE 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 LOVE 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: LOVE 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Cannara Biotech 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Cannara Biotech Inc., Annual General Meeting, Jan 30, 2025

These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively

New minor risk - Share price stability

Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings

Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue

Third quarter 2024 earnings released: EPS: CA$0.022 (vs CA$0.033 in 3Q 2023)

Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?

Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares

Second quarter 2024 earnings released: CA$0.038 loss per share (vs CA$0.007 loss in 2Q 2023)

Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today

First quarter 2024 earnings released: EPS: CA$0.023 (vs CA$0 in 1Q 2023)

Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking

Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point

Full year 2023 earnings released: EPS: CA$0.078 (vs CA$0.026 in FY 2022)

Insufficient new directors

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2024

Is Cannara Biotech (CVE:LOVE) A Risky Investment?

Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.016 in 3Q 2022)

Independent Director recently bought CA$60k worth of stock

Investor sentiment improves as stock rises 24%

Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 2Q 2022)

Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price

Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden

First quarter 2023 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2022)

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2023

Independent Director recently bought CA$117k worth of stock

Full year 2022 earnings released: EPS: CA$0.003 (vs CA$0.002 loss in FY 2021)

Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of Its First Vape Cartridge and Vape Accessory, Tribal G Mint and Uni Pro Ark

Independent Director recently bought CA$81k worth of stock

Third quarter 2022 earnings released: EPS: CA$0.002 (vs CA$0.002 in 3Q 2021)

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021)

Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Cannara Biotech Inc. Announces New Products Launch

Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cannara Biotech Inc. Receives Processing and Cultivation License

Cannara Biotech Inc. Receives Amendment of Its Licence from Health Canada Permitting the Sale of Cannabis 2.0 Products and Prepares for the Launch of Its Hash Product Line in Quebec

Third quarter 2021 earnings released: EPS CA$0.002 (vs CA$0.003 loss in 3Q 2020)

Cannara Biotech Inc. (TSXV:LOVE) completed the acquisition of Quebec Facility of Medican Organic Inc.

Cannara Biotech Inc. (TSXV:LOVE) entered into an agreement to acquire Quebec Facility of Medican Organic Inc. for CAD 32.7 million.

Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.004 loss in 1Q 2020)

Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?

Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?

Full year 2020 earnings released: CA$0.017 loss per share

Cannara Biotech Inc., Annual General Meeting, Jan 25, 2021

Cannara Biotech Inc. Appoints Donald Olds to Board of Directors

결제의 안정성과 성장

시장 대비 배당 수익률

주주에 대한 수익 배당금

주주에 대한 현금 배당금

강력한 배당금 지급 기업 알아보기